ArticleCNS neuroscience & therapeutics2025
Glymphatic System Dysfunction in Thyroid-Associated Ophthalmopathy: A Multimodal MRI Study.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glymphatic System Dysfunction in Thyroid-Associated Ophthalmopathy: A Multimodal MRI Study.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate glymphatic system (GS) alterations in thyroid-associated ophthalmopathy (TAO) patients and their links to clinical biomarkers, with the aim of understanding underlying mechanisms and potential therapeutic strategies.
methodsThis study included 28 active patients (AP), 25 inactive patients (IP) with TAO, and 37 healthy controls (HC), matched for age, sex, and educational level. Glymphatic function was evaluated using choroid plexus volume (CPV), diffusion tensor imaging along the perivascular space (DTI-ALPS) index, and coupling between global blood-oxygen-level-dependent signals and cerebrospinal fluid signals (gBOLD-CSF coupling). General linear regression analysis was conducted to explore the relationships between the GS and clinical parameters.
resultsSignificant differences were found in the ALPS index between the patient groups and the HC. Both the left (ALPS_L) and right (ALPS_R) ALPS indices, as well as the average ALPS index, were significantly lower in the AP and IP groups than in the HC (p < 0.01). The overall difference across all three groups was also significant (p < 0.01). However, no significant differences were observed between the AP and IP groups. However, no significant differences in CPV were observed between either the AP or IP group and the HC. Both the AP and IP groups exhibited lower gBOLD-CSF coupling than the HC (p = 0.001; p = 0.013). Significant correlations existed between GS function and clinical parameters in both groups.
conclusionTAO patients demonstrate significant GS impairments linked to neuropsychological symptoms and sleep disturbances. Targeting GS function may improve quality of life in TAO patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.